

Content

Index	Page No.
Chapter 1. Introduction	
1.1. Introduction	1
1.2. Objective of the Proposed Work	10
1.3. Rationale	10
1.4. Hypothesis	10
1.5. Research Design and Method	10
1.6. Expected Results	10
1.7. Work Plan	11
Reference list	12
Chapter 2. Literature Review	
2.1 Lung Cancer	19
2.2 Drug Profile	22
2.2.1 Mechanism of Action	22
2.2.2 Absorption, Fate, and Elimination	23
2.2.3 Therapeutic Uses	24
2.2.4 Clinical Toxicities	24
2.3 Nanoparticles	30
2.3.1 PLGA Nanoparticles	32
2.3.2 Characterization of nanoparticles	37
2.3.2.1 Particle size and morphology	38
2.3.2.2 Crystallinity	38
2.3.2.3 Surface charge	38
2.4 Methods of Preparation of Nanoparticles	39
2.4.1 Nanoparticles Prepared by Polymerization Process of Monomers	39
2.4.2 Nanoparticles Prepared from Dispersion of Preformed Polymers	40
2.5 Formulation Optimization	42
2.5.1 Experimental Designs	44

2.5.1.1	Factorial Designs	45
2.5.1.2	Design Augmentation	46
2.5.2	Response Surfaces	46
2.5.3	Mathematical Models	47
2.6	Antibody Structure and Function	48
2.6.1	Antibody Therapeutics for Cancer Therapy	51
2.6.1.1	Tumor Antigens	51
2.6.1.2	Mechanism of Tumor Killing	52
2.6.1.3	Current Antibody Therapeutics	53
	Reference list	55

Chapter 3. Analytical Method Development

3.1	Estimation Of Absorption Maxima Of Docetaxel	66
3.1.1	Equipment	67
3.1.2	Methods	67
3.1.2.1	Determination λ_{max}	67
3.1.2.2	Preparation of Stock Solution	67
3.1.2.3	Preparation of Calibration Curve in Acetonitrile	67
3.2	Analytical Method Validation	68
3.2.1	Linearity	68
3.2.2	Accuracy	68
3.2.3	Precision	68
3.2.4	Limit of Detection and Limit of Quantification	68
3.3	Results and Discussion	69
3.3.1	Determination of λ_{max}	69
3.3.2	Calibration Curve of Docetaxel	69
3.3.3	Results of Analytical Method Validation	70
3.4	Conclusion	71
	Reference list	72

Chapter 4. Formulation Development

4.1	Introduction	74
4.2	Preparation of Docetaxel-Loaded Nanoparticles By Emulsification Solvent Evaporation Method	77
4.2.1	Method	77
4.3	Preliminary Optimization of Parameters	78
4.4	Optimization by Factorial Design	79
4.5	Lyophilization of Docetaxel Loaded Nanoparticles and Optimization of Cryoprotectant	81
4.6	Characterization of Optimized Docetaxel Loaded Nanoparticles	82
4.6.1	Particle Size	82
4.6.2	Entrapment Efficiency and Drug Loading	82
4.6.3	Zeta Potential	82
4.7	Results and Discussion	83
4.7.1	Optimization by Factorial Design	83
	<i>i. Statistical Analysis of Response Particle Size</i>	84
	<i>ii. Statistical Analysis of PDI</i>	90
	<i>iii. Statistical Analysis of % drug loading</i>	95
	<i>iv. Selection of Optimized Batch:</i>	101
	<i>v. Point Prediction and Confirmation:</i>	101
4.8	Lyophilization and optimization of cryoprotectant concentration	102
4.9	Antibody conjugation of nanoparticles	102
4.9.1	Estimation of conjugation efficiency of antibody to the nanoparticles	103
4.9.2	Optimization for conjugation of Cetuximab in Docetaxel loaded Nanoparticles	104
4.9.2.1	Influence of pH on conjugation efficiency	104
4.9.2.2	Influence of temperature on conjugation efficiency	104
4.9.2.3	Influence of amount of activating agent [EDC-HCl/NHS concentration]	104
4.9.2.4	Influence of reaction time	105

4.9.2.5	Influence of amount of antibody	105
4.9.3	Characterization of immunonanoparticles	105
4.9.3.1	Particle size and zeta potential	105
4.9.3.2	In-vitro drug release	105
4.9.5	Determination of residual dichloromethane/chloroform in nanoparticles	106
4.10	Results and Discussion	106
4.10.1	Lyophilization and optimization of cryoprotectant concentration	106
4.10.2	Antibody conjugation of nanoparticles	107
4.10.3	Particle size, zeta potential and drug entrapment efficiency	110
4.10.4	In-vitro drug release	111
4.10.5	Determination of residual ethyl acetate in nanoparticles	112
	Reference list	113

Chapter 5. In vitro characterization

5.1	Cell-line Studies	121
5.1.1	In Vitro Cytotoxicity Assay (MTT Assay)	121
5.1.2	Confocal microscopy observation	122
5.1.3	Cellular uptake by flow cytometer analysis	123
5.1.4	Apoptosis study	123
5.1.5	Cell cycle analysis by flow cytometry	123
5.2	Results and Discussion	125
5.2.1	In Vitro Cytotoxicity Assay (MTT Assay)	125
5.2.2	Confocal microscopy observation	131
5.2.3	Cellular uptake by flow cytometry	133
5.2.4	Cell apoptosis analysis	136
5.2.5	Cell cycle analysis	139
	Reference list	142

Chapter 6. In vivo efficacy study

6.1	In Vivo Efficacy Study	146
6.1.1	Description of the Methods	146
6.2	Results and Discussion	146
6.3	Conclusions	148
	Reference list	149

Chapter 7. Stability Studies

7.1	Stability Studies of Nanoparticles	151
7.2	Results and Discussion	152
7.2.1	Stability Testing Docetaxel Nanoparticles	152
	Reference list	155

Chapter 8. Summary & Conclusions

8.1	Summary	156
8.2	Conclusions	162